IP Library Granted Patent US 10,047,144
Granted Patent B2
US 10,047,144 · App. 13/655,955 · Granted Aug 14, 2018

Methods of purifying antibodies

Inventors: Greg Elson (Collonges Sous Saleve, FR); Nicolas Fouque (Collonges Sous Saleve, FR); Jean-Francois Depoisier (Mont Saxonnet, FR); Nicolas Fischer (Geneva, CH); Giovanni Magistrelli (Cessay, FR)
Assignee: NovImmune SA
C07K16/00C07K16/248C07K16/249C07K16/2866C07K16/468C07K2317/32C07K2317/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,047,144
App. No.
13/655,955
Granted
Aug 14, 2018
Kind
B2
Abstract

The invention provides methods of purifying antibodies using various antibody-specific purification media to rapidly and efficiently separate mixtures of antibodies, antibody fragments and/or antibody components to isolate a desired antibody product from the mixture. The invention relates to the purification of bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, e.g., antibodies composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain, including antibodies of different specificities that share a common heavy chain. The invention also provides the methods of efficiently purifying intact antibodies by separating the intact antibody from non-intact antibodies including free light chains.

Claims (20)

1. A method of purifying a bispecific antibody consisting of two copies of a single heavy chain polypeptide and a first light chain comprising a kappa constant region and a second light chain comprising a lambda constant region (κλ-bodies), the method consisting of the steps:

(a) providing a mixed antibody composition comprising κλ-bodies; one or more monospecific monoclonal antibodies having two lambda light chains (λ-MAb); and one or more monospecific monoclonal antibodies having two kappa light chains (κ-MAb);

(b) providing a separation means that has specific affinity for a kappa light chain constant region or a lambda light chain constant region;

(c) contacting the separation means with the mixed antibody composition under conditions that allow for the mixed antibody composition to specifically bind the separation means;

(d) washing the separation means to elute impurities;

(e) eluting the κλ-bodies under conditions that allow for preferential detachment of the κλ-bodies thereby purifying the κλ-bodies.

2. The method of claim 1 , wherein the separation means having specific affinity for kappa light chain constant region is

a resin, a membrane, a magnetic bead, a particle or a monolith coupled to a ligand having specific affinity for the kappa light chain constant region; and the separation means having specific affinity for lambda light chain constant region is

a resin, a membrane, a magnetic bead, a particle or a monolith coupled to a ligand having specific affinity for the lambda light chain constant region.

3. The method of claim 1 , wherein the elution conditions comprise a step variation in the pH level.

4. The method of claim 1 , wherein the elution conditions comprise a variation of the concentration of an amino acid in the composition.

5. The method of claim 4 , wherein the amino acid is arginine, histidine, proline, phenylalanine, tyrosine, tryptophan and/or glycine.

6. A single step affinity chromatography method of purifying a bispecific antibody consisting of two copies of a single heavy chain polypeptide and a first light chain comprising a kappa constant region and a second light chain comprising a lambda constant region (κλ-bodies), the method consisting of:

(a) providing a mixed antibody composition comprising κλ-bodies; one or more monospecific monoclonal antibodies having two lambda light chains (λ-MAb); and one or more monospecific monoclonal antibodies having two kappa light chains (κ-MAb);

(b) providing a separation means, wherein the separation means is an anti-kappa light chain antibody, or an anti-lambda light chain antibody coupled to a solid support;

(c) contacting the separation means with the mixed antibody composition under conditions that allow for the mixed antibody composition to specifically bind the separation means;

(d) washing the separation means to elute impurities with a wash solution having a pH of about 7.0 or higher; and

(e) eluting specifically the κλ-bodies with an elution solution having a pH of about 3.0, thereby purifying the κλ-bodies.

7. The method of claim 6 , wherein the solid support is a resin, a membrane, a magnetic bead, a particle or a monolith.

8. The method of claim 6 , wherein the solid support is a highly cross-linked agarose.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2013
From: ELSON, GREG; FOUQUE, NICOLAS; DEPOISIER, JEAN-FRANCOIS; FISCHER, NICOLAS; MAGISTRELLI, GIOVANNI
To: NOVIMMUNE S.A.
Reel/Frame 030952/0355 →
Continuity (2)
Provisional Application 61548958 · Oct 19, 2011
Related Publication 20130317200A1 · Nov 28, 2013